Metabolomics Analysis Identifies Intestinal Microbiota-Derived Biomarkers of Colonization Resistance in Clindamycin-Treated Mice

Background The intestinal microbiota protect the host against enteric pathogens through a defense mechanism termed colonization resistance. Antibiotics excreted into the intestinal tract may disrupt colonization resistance and alter normal metabolic functions of the microbiota. We used a mouse model to test the hypothesis that alterations in levels of bacterial metabolites in fecal specimens could provide useful biomarkers indicating disrupted or intact colonization resistance after antibiotic treatment. Methods To assess in vivo colonization resistance, mice were challenged with oral vancomycin-resistant Enterococcus or Clostridium difficile spores at varying time points after treatment with the lincosamide antibiotic clindamycin. For concurrent groups of antibiotic-treated mice, stool samples were analyzed using quantitative real-time polymerase chain reaction to assess changes in the microbiota and using non-targeted metabolic profiling. To assess whether the findings were applicable to another antibiotic class that suppresses intestinal anaerobes, similar experiments were conducted with piperacillin/tazobactam. Results Colonization resistance began to recover within 5 days and was intact by 12 days after clindamycin treatment, coinciding with the recovery bacteria from the families Lachnospiraceae and Ruminococcaceae, both part of the phylum Firmicutes. Clindamycin treatment caused marked changes in metabolites present in fecal specimens. Of 484 compounds analyzed, 146 (30%) exhibited a significant increase or decrease in concentration during clindamycin treatment followed by recovery to baseline that coincided with restoration of in vivo colonization resistance. Identified as potential biomarkers of colonization resistance, these compounds included intermediates in carbohydrate or protein metabolism that increased (pentitols, gamma-glutamyl amino acids and inositol metabolites) or decreased (pentoses, dipeptides) with clindamycin treatment. Piperacillin/tazobactam treatment caused similar alterations in the intestinal microbiota and fecal metabolites. Conclusions Recovery of colonization resistance after antibiotic treatment coincided with restoration of several fecal bacterial metabolites. These metabolites could provide useful biomarkers indicating intact or disrupted colonization resistance during and after antibiotic treatment.

[1]  V. Mai,et al.  Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.

[2]  C. Donskey,et al.  Effective and Reduced-Cost Modified Selective Medium for Isolation of Clostridium difficile , 2008, Journal of Clinical Microbiology.

[3]  S. Finegold,et al.  Intestinal beta-lactamase activity in ampicillin-induced, Clostridium difficile-associated ileocecitis. , 1983, The Journal of infectious diseases.

[4]  H. Ashrafian,et al.  Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. , 2011, Trends in microbiology.

[5]  L. Rice,et al.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. , 2000, The New England journal of medicine.

[6]  Neil Hunter,et al.  Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. , 2002, Microbiology.

[7]  Pelin Yilmaz,et al.  The SILVA ribosomal RNA gene database project: improved data processing and web-based tools , 2012, Nucleic Acids Res..

[8]  M. Mcmurdo,et al.  Characterization of Bacterial Communities in Feces from Healthy Elderly Volunteers and Hospitalized Elderly Patients by Using Real-Time PCR and Effects of Antibiotic Treatment on the Fecal Microbiota , 2004, Applied and Environmental Microbiology.

[9]  C. Donskey,et al.  Vegetative Clostridium difficile Survives in Room Air on Moist Surfaces and in Gastric Contents with Reduced Acidity: a Potential Mechanism To Explain the Association between Proton Pump Inhibitors and C. difficile-Associated Diarrhea? , 2007, Antimicrobial Agents and Chemotherapy.

[10]  Taane G. Clark,et al.  Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice , 2012, PLoS pathogens.

[11]  Patrick D Schloss,et al.  The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection , 2011, Gut microbes.

[12]  Michael A Kennedy,et al.  NMR‐based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad‐spectrum antibiotic enrofloxacin (Baytril) , 2009, Magnetic resonance in chemistry : MRC.

[13]  F. Bäckhed,et al.  Host-Bacterial Mutualism in the Human Intestine , 2005, Science.

[14]  J. Koopman,et al.  Biochemical effects on germ-free mice of association with several strains of anaerobic bacteria. , 1980, Journal of general microbiology.

[15]  G. Macfarlane,et al.  Bacteria, colonic fermentation, and gastrointestinal health. , 2012, Journal of AOAC International.

[16]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[17]  E. Stadtman,et al.  Comparative Biochemical and Immunological Studies of Bacterial Glutamine Synthetases , 1973, Journal of bacteriology.

[18]  Michael Wagner,et al.  probeBase: an online resource for rRNA-targeted oligonucleotide probes , 2003, Nucleic Acids Res..

[19]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[20]  D. Portetelle,et al.  Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time PCR. , 2008, Microbiological research.

[21]  K. Chung,et al.  Formation of indoleacetic acid by intestinal anaerobes , 1975, Journal of bacteriology.

[22]  Y. Carmeli,et al.  Rectal Swabs Are Suitable for Quantifying the Carriage Load of KPC-Producing Carbapenem-Resistant Enterobacteriaceae , 2013, Antimicrobial Agents and Chemotherapy.

[23]  M. Wyss,et al.  Creatine and creatinine metabolism. , 2000, Physiological reviews.

[24]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[25]  David A Stephens,et al.  Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection , 2013, Microbiome.

[26]  Bo Li,et al.  Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection , 2014, Nature Communications.

[27]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[29]  W. R. Wikoff,et al.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.

[30]  C. Donskey,et al.  Effect of Antibiotic Treatment on Growth of and Toxin Production by Clostridium difficile in the Cecal Contents of Mice , 2005, Antimicrobial Agents and Chemotherapy.

[31]  Katharine G. Field,et al.  A PCR Assay To Discriminate Human and Ruminant Feces on the Basis of Host Differences in Bacteroides-Prevotella Genes Encoding 16S rRNA , 2000, Applied and Environmental Microbiology.

[32]  D. van der Waaij,et al.  Colonization resistance of the digestive tract in conventional and antibiotic-treated mice , 1971, Journal of Hygiene.

[33]  T. Louie,et al.  Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. van der Waaij,et al.  Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. , 1971 .

[35]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[36]  H. Adlercreutz,et al.  Interindividual Variation in Metabolism of Soy Isoflavones and Lignans: Influence of Habitual Diet on Equol Production by the Gut Microflora , 2000, Nutrition and cancer.

[37]  J. Fujimoto,et al.  Development of 16S rRNA-Gene-Targeted Group-Specific Primers for the Detection and Identification of Predominant Bacteria in Human Feces , 2002, Applied and Environmental Microbiology.

[38]  A. Palva,et al.  Development of an extensive set of 16S rDNA‐targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real‐time PCR , 2004, Journal of applied microbiology.

[39]  C. Donskey,et al.  Increased Susceptibility to Vancomycin-Resistant Enterococcus Intestinal Colonization Persists After Completion of Anti-Anaerobic Antibiotic Treatment in Mice , 2004, Infection Control & Hospital Epidemiology.

[40]  B. Weimer,et al.  Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens , 2013, Nature.

[41]  A. Viale,et al.  Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis , 2011, Infection and Immunity.

[42]  A. Walker,et al.  Intestinal colonization resistance , 2013, Immunology.

[43]  Elaine Holmes,et al.  Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. , 2008, Journal of proteome research.

[44]  I. Wilson,et al.  Variation in antibiotic-induced microbial recolonization impacts on the host metabolic phenotypes of rats. , 2011, Journal of proteome research.

[45]  Corey D. DeHaven,et al.  Categorizing Ion -Features in Liquid Chromatography/Mass Spectrometry Metobolomics Data , 2012 .

[46]  M. Blaut,et al.  Metabolic diversity of the intestinal microbiota: implications for health and disease. , 2007, The Journal of nutrition.

[47]  R. Rolfe.  Role of volatile fatty acids in colonization resistance to Clostridium difficile , 1984, Infection and immunity.

[48]  S. Segal,et al.  The metabolism of D-ribose in man. , 1958, The Journal of clinical investigation.

[49]  C. Donskey,et al.  Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole , 2013, PloS one.

[50]  Vincent B. Young,et al.  Suppression of Clostridium difficile in the Gastrointestinal Tracts of Germfree Mice Inoculated with a Murine Isolate from the Family Lachnospiraceae , 2012, Infection and Immunity.

[51]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .